Skip to main content
. 2021 Apr 9;9(9):969–976. doi: 10.1016/S2213-2600(21)00043-6

Figure 4.

Figure 4

Kaplan–Meier cumulative survival analyses according to TMB (post-hoc analysis)

Kaplan–Meier overall survival for all patients in the NIBIT-MESO-1 study with samples available for TMB analysis. Vertical lines indicate censored observations. (A) Overall survival of patients stratified by median TMB of less than 8·3 and more than 8·3 mutations per Mb (n=28). (B) Overall survival of patients stratified by median TMB of less than 8·3 and more than 8·3 mutations per Mb in patients retreated with tremelimumab and durvalumab (n=13). TMB=tumour mutational burden.